Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.67 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.67 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without providing detailed guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.
Madrigal Pharmaceuticals reported a loss per share of $0.67, which was in line with expectations, but no revenue figures were disclosed. The stock fell by 1.88% following the earnings report, reflecting investor concerns over the lack of guidance and clarity on future performance. The focus remains on their clinical programs, but uncertainty may weigh on investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Acuity Inc.
Apr 4, 2017